ArticleJournal of hepatocellular carcinoma2026
Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety.
Lin Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.